image002[2].png
Notable Labs Closes Merger Transaction With VBL Therapeutics
16 oct. 2023 13h01 HE | Notable Labs
- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 - - Aggregate net transaction proceeds expected to fund planned...
image002[2].png
Notable Labs Presents Data Demonstrating PPMP’s Potential to Identify Novel Drug Combinations in JMML at the 2023 EHA Hybrid Congress
09 juin 2023 08h00 HE | Notable Labs
– Data demonstrates Notable’s PPMP potential in selecting more active investigational pre-hematopoietic stem cell therapy drug combinations, as compared to regimens currently used in JMML – FOSTER...
image002[2].png
Notable Labs to Present Predictive Precision Medicine Platform (PPMP) Data in Juvenile Myelomonocytic Leukemia (JMML) at European Hematology Association (EHA) Hybrid Congress June 8 – 15, 2023
17 mai 2023 07h00 HE | Notable Labs
FOSTER CITY, Calif., May 17, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients,...
image002[2].png
Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting
18 avr. 2023 09h00 HE | Notable Labs
- 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning - - Fourth clinical validation study of Predictive Precision Medicine Platform - FOSTER CITY,...
image002[2].png
Notable Labs to Present Results from Clinical Platform Validation Study at the 2023 American Association for Cancer Research (AACR) Annual Meeting
14 mars 2023 16h30 HE | Notable Labs
FOSTER CITY, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Notable Labs, Inc. (“Notable”), a clinical stage therapeutic platform company developing predictive precision medicines for cancer patients,...
NotableLabs-Logo-07 (2).png
Notable to Host July 23 Webinar with Stanford Cancer Institute and MDS Foundation: Emerging Treatment Approaches for Higher Risk Myelodysplastic Syndromes
13 juil. 2020 11h00 HE | Notable Labs
FOSTER CITY, Calif., July 13, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...
Joseph Wagner Headshot
Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer
08 juil. 2020 11h00 HE | Notable Labs
FOSTER CITY, Calif., July 08, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...
precision oncology in hematological cancers
Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies
23 juin 2020 11h00 HE | Notable Labs
FOSTER CITY, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today...
NotableLabs-Logo-07 (2).png
Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients
30 avr. 2020 11h00 HE | Notable Labs
FOSTER CITY, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, announced a...
NotableLabs-Logo-07 (2).png
Notable Announces Leadership Team Expansion
09 avr. 2020 14h03 HE | Notable Labs
SAN FRANCISCO, April 09, 2020 (GLOBE NEWSWIRE) -- Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its...